Exchange: OTC | Sector: Healthcare | Industry: Medical Healthcare Information Services
Q4 2024
Published: Oct 10, 2024
Earnings Highlights
EPS of $0.00 increased by 89.5% from previous year
Net income of -4.61K
"Transcript not provided in the dataset." - Management
PreAxia Health Care Payment Systems Inc (PAXH) QQ4 2024 Earnings Analysis – Severe liquidity stress and negative profitability in Healthcare IT Payments
Executive Summary
PreAxia Health Care Payment Systems Inc (PAXH) reports aQ4 2024 period with no disclosed revenue data and a pronounced earnings deficit, recording net income of -$4,611 and an associated EPS of -$0.0002 on 19.767 million weighted shares. Operating loss of -$4,611 and EBITDA of -$4,611 are accompanied by a material one-off positive contribution labeled as 'totalOtherIncomeExpensesNet' of $99,449, which appears to be an anomalous or non-operational item rather than recurring operating earnings. Free cash flow and operating cash flow are negative (-$3,635 and -$3,635, respectively) with cash at period-end of $14 versus $1,194 at the start, underscoring an acute cash-burn profile over the recent quarters. The balance sheet exhibits an asset base of only $14 against total liabilities of $2.40 billion, yielding a deeply negative equity position (-$2.396 billion) and a leveraged, liquidity-constrained balance sheet. Management commentary is not available in the provided transcript dataset; no earnings-call quotes are provided. The company’s stated business focus remains healthcare payment processing services and health spending accounts, but the current financials reflect a distressed balance-sheet scenario that requires near-term liquidity solutions or strategic restructuring to restore credibility with capital markets. Investors should treat PAXH as an extremely high-risk position with a low likelihood of near-term profitability absent a material revenue-generating pivot or capital infusion.
Net Income: -$4,611; YoY +87.65%, QoQ +47.66% (loss level remains, but the magnitude improvement is from a negative base).
EBITDA: -$4,611 (negative due to operating losses).
EPS: -$0.0002; YoY +89.47%, QoQ +50.00% (negative earnings persist but per-share loss is marginal).
Total assets: $14; Cash and cash equivalents: $14; Retained earnings: -$5,128,380; Total liabilities: $2,396,193; Total stockholders’ equity: -$2,396,179.
Financial Highlights
Revenue: Not disclosed in the presented data; no YoY/QoQ revenue basis available.
Profitability:
- Operating Income: -$4,611; YoY +87.65%, QoQ +47.66% (negative baseline continues to reflect losses).
- Net Income: -$4,611; YoY +87.65%, QoQ +47.66% (loss level remains, but the magnitude improvement is from a negative base).
- EBITDA: -$4,611 (negative due to operating losses).
- EPS: -$0.0002; YoY +89.47%, QoQ +50.00% (negative earnings persist but per-share loss is marginal).
Balance Sheet and Cash Flow:
- Total assets: $14; Cash and cash equivalents: $14; Retained earnings: -$5,128,380; Total liabilities: $2,396,193; Total stockholders’ equity: -$2,396,179.
- Net debt: $1,717,291; Debt: $1,717,305.
- Current ratio: 0.0000058; Cash ratio: 0.0000058; Quick ratio: 0.0000058 — indicating extreme liquidity stress.
- Net cash used in operating activities: -$3,635; Free cash flow: -$3,635; Cash at end of period: $14; Cash at beginning: $1,194.
Notes:
- The dataset shows a large positive 'totalOtherIncomeExpensesNet' of $99,449 in Q4, which is atypical for core operating performance and may reflect non-cash or one-time adjustments rather than recurring revenue-generation capability.
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-4.61K
87.65%
47.66%
Net Income
-4.61K
87.65%
47.66%
EPS
0.00
89.47%
50.00%
Key Financial Ratios
currentRatio
0
returnOnAssets
-32936%
returnOnEquity
0.19%
debtEquityRatio
-0.72
operatingCashFlowPerShare
$-0
freeCashFlowPerShare
$-0
priceToBookRatio
-0.47
priceEarningsRatio
-61.09
Net Income vs. Revenue
Expense Breakdown
Management Commentary
Transcript data is not provided in the dataset. As a result, there are no management quotes or thematic insights from an earnings call to quote or contextualize in relation to the results. Reportedly, no earnings transcript is available for the QQ4 2024 period in the supplied information. If/when transcript data is provided, quotes should be grouped by themes (strategy, operations, market conditions) with context and significance.
Transcript not provided in the dataset.
— Management
Transcript not provided in the dataset.
— Management
Forward Guidance
No forward guidance is contained in the provided dataset. Given the current financials — negligible assets, substantial liabilities, negative equity, and negative cash flow — management guidance would need to address liquidity runway, potential capital raises, debt restructuring, and a credible path to revenue recognition. Absent a material reversal in revenue generation or a clear recapitalization plan, the achievability of any near-term targets remains highly uncertain. Investors should monitor: (1) any upcoming financing arrangements or debt restructuring terms, (2) progress in a potential pivot to monetizable healthcare payment solutions, (3) visibility on product/contractual revenue pipelines, and (4) updated liquidity forecasts and working-capital optimization.
Competitive Position
Company
Gross Margin
Operating Margin
Return on Equity
P/E Ratio
PAXH Focus
0.00%
0.00%
0.19%
-61.09%
FOXO
63.30%
-21.80%
27.40%
-15.80%
JRSS
12.50%
1.09%
-1.91%
69.25%
MITI
50.00%
-14.70%
-9.75%
3.03%
ONMD
0.99%
-11.63%
1.42%
-81.90%
Gross Profit Margin
Operating Profit Margin
Return on Equity
P/E Ratio Comparison
Investment Outlook
High-risk, high-uncertainty scenario. Based on the QQ4 2024 data, PAXH shows no disclosed revenue, a severely dilapidated asset base, and substantial liabilities resulting in negative equity. The stock’s implied value, liquidity runway, and earnings prospects appear unattractive absent a meaningful capital infusion, a credible revenue trajectory, or a strategic pivot validated by customers and partners. The investment stance is to avoid or to consider only with explicit, near-term liquidity plans and a clear path to revenue. Key catalysts to watch include announced financing discussions, debt restructuring terms, and any verifiable revenue-generating agreements or partnerships that can meaningfully improve cash flow and solvency metrics within a defined runway.
Key Investment Factors
Growth Potential
Low given the current lack of disclosed revenue and negative earnings; potential hinges on a successful monetization of healthcare payment processing platforms, strategic partnerships, or a substantial capital infusion enabling a pivot and scale. Any realized growth would require a credible revenue path and credible funding to support scale.
Profitability Risk
Severe liquidity risk and solvency risk due to assets of $14 versus liabilities of $2.396 billion; negative equity; ongoing cash burn; reliance on non-operating income items; lack of disclosed revenue; potential for debt restructuring and capital raises; high execution risk in a niche market dominated by larger incumbents.
Financial Position
Distressed balance sheet with negligible assets and substantial liabilities; negative equity of approximately -$2.396 billion; net debt of $1.717 billion; current and quick ratios near zero; earnings quality is questionable given the absence of revenue data and reliance on unusual one-time items.
SWOT Analysis
Strengths
Business focus on health care payment processing and health spending accounts addresses a sizable structural market in healthcare administration.
Description of product scope suggests potential for scalable platform-enabled services with partnerships (TBD).
Weaknesses
Extreme liquidity strain with total assets of $14 against liabilities of $2.396 billion.
No disclosed revenue in QQ4 2024; persistent net losses and negative equity.
Limited tangible operating cash flow and a fragile balance sheet raise financing and solvency concerns.
Opportunities
Industrywide trend toward digitization of healthcare payments and spending accounts could unlock monetizable revenue streams if executed efficiently.
Possibility of strategic partnerships, licensing of technology, or M&A activity to realize value and stabilize liquidity.
Threats
Competitive intensity from established healthcare IT and payment processors with stronger balance sheets.
Regulatory/compliance risks in healthcare payments and data handling; potential for capital market disfavor in a distressed capital structure.
Continued reliance on one-time or non-operating items for reported income undermines earnings credibility and could impact funding costs.
PreAxia Health Care Payment Systems Inc (PAXH) QQ2 2024 Earnings Review – Weak Revenue Visibility, Acute Liquidity Strains, and Cash Burn in Healthc...